|1.||Techner, Lee: 12 articles (08/2014 - 10/2004)|
|2.||Delaney, Conor P: 8 articles (01/2015 - 06/2005)|
|3.||Du, Wei: 8 articles (01/2010 - 10/2004)|
|4.||Wolff, Bruce G: 5 articles (09/2010 - 10/2004)|
|5.||Becker, Gerhild: 3 articles (03/2015 - 11/2007)|
|6.||Svatek, Robert S: 3 articles (08/2014 - 06/2013)|
|7.||Kurz, Andrea: 3 articles (08/2014 - 01/2003)|
|8.||Senagore, Anthony J: 3 articles (12/2011 - 03/2007)|
|9.||Pierce, Amy: 3 articles (02/2011 - 07/2008)|
|10.||Senagore, Anthony: 2 articles (11/2015 - 09/2010)|
10/01/2005 - "Alvimopan is effective in treating postsurgical ileus and perhaps opiate-induced bowel dysfunction. "
09/01/2007 - "Is alvimopan a safe and effective treatment for postoperative ileus?"
01/01/2008 - "The efficacy of alvimopan in the management of postoperative ileus has been evaluated in five phase III trials; four conducted in North America and one conducted in Europe/Australasia. "
08/01/2008 - "Clinical trial: alvimopan for the management of post-operative ileus after abdominal surgery: results of an international randomized, double-blind, multicentre, placebo-controlled clinical study."
05/01/2008 - "Pharmacokinetics of alvimopan and its metabolite in healthy volunteers and patients in postoperative ileus trials."
10/01/2004 - "Thus, alvimopan may be useful for the treatment of gastrointestinal sequelae following opiate treatment for postoperative or chronic pain."
04/01/2006 - "Combined with other options aimed at reducing opioid burden, alvimopan and similar drugs in development hold promise as part of multimodal protocols to optimize pain management while minimizing postoperative morbidities."
03/01/2005 - "We evaluated oral alvimopan, 0.5 or 1 mg, versus placebo, once daily for 21 days, in 168 patients with opioid-induced bowel dysfunction (OBD) who were receiving chronic opioid therapy (minimum, 1 month) for nonmalignant pain (n = 148) or opioid dependence (n = 20). "
11/01/2001 - "Analgesia was not compromised, because there were no changes in median opioid consumption or Visual Analog Scale (VAS) pain scores in patients treated with ADL 8-2698 versus patients treated with placebo. "
02/01/2011 - "A randomized, placebo-controlled phase 3 trial (Study SB-767905/012) of alvimopan for opioid-induced bowel dysfunction in patients with non-cancer pain."
02/01/2011 - "This double-blind, placebo-controlled trial was conducted as part of a recently discontinued clinical program, in which alvimopan was being developed for opioid-induced constipation (OIC). "
02/01/2011 - "Alvimopan was under clinical development for long-term treatment of opioid-induced constipation (OIC) but this program has been discontinued. "
10/15/2007 - "Both methylnaltrexone and alvimopan also appear effective for treating opioid-induced constipation. "
09/01/2008 - "Meta-analysis demonstrated that methylnaltrexone and alvimopan are efficacious in reversing opioid-induced increased gastrointestinal transit time and constipation, and that alvimopan is safe and efficacious in treating postoperative ileus. "
01/01/2008 - "Meta-analysis demonstrated that methylnaltrexone and alvimopan were better than placebo in reversing opioid-induced increased gastrointestinal transit time and constipation, and that alvimopan appears to be safe and efficacious in treating postoperative ileus. "
04/01/2015 - "From a pharmacological perspective, a meta-analysis of pro-kinetics showed beneficial results with alvimopan, although its use has been limited by the augmented risk of myocardial infarction and the high costs. "
09/01/2009 - "A higher incidence of myocardial infarction was observed in a 12-month study of alvimopan for the treatment of opioid-induced bowel dysfunction, but not in studies in patients undergoing bowel resection. "
04/04/2009 - "Alvimopan was recently approved by the FDA for treatment of postoperative ileus, but the use of the drug is restricted to inpatients because it has been associated with an increased rate of myocardial infarction. "
10/01/2014 - "Although hastened patient recovery is clearly multifactorial, our pathway, incorporating alvimopan, early feeding strategies, and multimodal pain therapy with an emphasis on the reduction of opiate usage as well as precise intraoperative nerve block with novel longer-acting local anesthetic Exparel, appears to provide significant improvement in postoperative pain, bowel function recovery, and shorter hospital stay. "
|1.||mu Opioid Receptors (mu Opioid Receptor)
|3.||Opioid Analgesics (Opioids)
|5.||Opioid Receptors (Opioid Receptor)
|6.||Morphine (MS Contin)
|8.||Cocaine (Cocaine HCl)
|10.||Narcotic Antagonists (Opioid Antagonists)
|2.||Length of Stay
|4.||Nerve Block (Nerve Blocks)